---
title: "ACR20 reached 92.5%, surpassing 72.7% at week 16 and meeting expectations. — 하나증권 제약/바이오 김선아 — DecisionGateway"
description: "statement by 하나증권 제약/바이오 김선아, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1d887-39a1-7a6b-bd1a-2c21ac06e0c4"
meta:
  "og:description": "statement by 하나증권 제약/바이오 김선아, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "ACR20 reached 92.5%, surpassing 72.7% at week 16 and meeting expectations. — 하나증권 제약/바이오 김선아 — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

statement

# **ACR20 reached 92.5%, surpassing 72.7% at week 16 and meeting expectations.**

A statement by 하나증권 제약/바이오 김선아. Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *ACR20 92.5%로 16주차 72.7%를 넘어서며 기대 수치 충족*

hanaresearchPublished 2026-11-10 [ Read source](https://t.me/hanaresearch/20929)

## **Discussion**

## **Related claims**

[**In the 600mg high-dose maintenance group, the ACR20 response rate was 92.5%, with nearly all patients maintaining response through week 28.**현대차증권 제약/바이오/의료기기 김현석 · statement](https://dgw.tmarket.io/claims/01a1d950-db21-760b-a0d0-62b887471209) [**The 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.**report author · statement](https://dgw.tmarket.io/claims/01a1d4b6-f6e3-7be5-ab83-bf2b785418ad) [**The high placebo response rate is because all patients received 600mg high dose for 16 weeks in Period 1, not because of a large placebo effect; 75% of the placebo group maintained ACR20 through week 28.**현대차증권 제약/바이오/의료기기 김현석 · statement](https://dgw.tmarket.io/claims/01a1d950-db45-7c00-9e32-c82440862863) [**IMVT-1402 in refractory rheumatoid arthritis achieved statistical significance in the Period 2 ACR20 response rate, with the 600mg group meeting key endpoints at week 28 on both ACR20 and ACR50 versus placebo.**현대차증권 제약/바이오/의료기기 김현석 · statement](https://dgw.tmarket.io/claims/01a1d950-db09-704e-b002-22ff5c6d58f3) [**The AWACRI index was unchanged at 19.80%.**avestagroupuz · statement](https://dgw.tmarket.io/claims/01a1ca79-5769-7d5f-a24c-d8abce7abf93) [**AWACRI was unchanged at 19.80%, 5.80% above the Central Bank policy rate of 14%, because no bonds were placed or redeemed during the week.**avestagroupuz · statement](https://dgw.tmarket.io/claims/01a1ca7c-23b1-7f67-97cd-01a27a4682ce)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 4,000+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1d887-39a1-7a6b-bd1a-2c21ac06e0c4#webpage","@type":"WebPage","description":"statement by 하나증권 제약/바이오 김선아, recorded recently — verbatim quote and source citation.","name":"ACR20 reached 92.5%, surpassing 72.7% at week 16 and meeting expectations. — 하나증권 제약/바이오 김선아 — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1d887-39a1-7a6b-bd1a-2c21ac06e0c4","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1d887-39a1-7a6b-bd1a-2c21ac06e0c4#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1d887-39a1-7a6b-bd1a-2c21ac06e0c4"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1d887-39a1-7a6b-bd1a-2c21ac06e0c4#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"ACR20 reached 92.5%, surpassing 72.7% at week 16 and…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1d887-39a1-7a6b-bd1a-2c21ac06e0c4#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-10","isBasedOn":"https://t.me/hanaresearch/20929","text":"ACR20 92.5%로 16주차 72.7%를 넘어서며 기대 수치 충족","url":"/claims/01a1d887-39a1-7a6b-bd1a-2c21ac06e0c4"}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.